"Alida Biosciences Secures $7.5M for Product Development and Market Entry"

Alida Biosciences raises $7.5M in Series A Funding

Alida Biosciences (Linkedin), a leader in epigenomic research tools, has secured $7.5M in Series A funding to advance their product development and bring the EpiPlex kit to market. Their innovative solutions cater to researchers and scientists in the field of epigenomics and life sciences, with a focus on multiplexed epitranscriptomic analysis of clinical research RNA samples.

Funding Amount: $7.5 million

Industry: Biotechnology Research

Employee Count: 11-50

CEO: Gudrun Stengel (CEO Linkedin)

What Alida Biosciences needs to buy: Alida Biosciences is seeking collaborations with research institutions, technology partners, and academic institutions to enhance and expand their product offerings. Companies specializing in product development, marketing and sales support, and research and development partnerships are ideal partners for Alida Biosciences as they continue to advance epigenomic research and develop new tools and technologies.